3D tumor models for CAR-T-cell therapy optimization

03:252 years ago

Chimeric antigen receptor (CAR) T-cell therapy accounts for one of the most promising therapeutic advances in cancer immunotherapy. In this form of adoptive cell transfer, T-cells of a patient are engineered to express so-called ‘CARs’, in which the antigen-recognition capacity of antibodies is combined with T-cell activating domains. So far, CAR-T-cell therapy obtained its most impressive results in hematological malignancies resulting in the approval of five CAR-T cell products by the FDA for hematologic indications. However, CAR-T-cell therapy has not mirrored its success in solid tumors. The poor efficacy of CAR-T-cell therapy in solid tumors has, in part, been attributed to the lack of understanding in how CAR-T-cells function in a solid tumor microenvironment. Classical validation methods rely on the use of specificity and functionality assays in 2D models against adherent target cells or target cells in suspension. Yet, by using these models, observations made in vitro may differ greatly to an in vivo situation where tumors are engrafted in 3D structures. We developed a more relevant and translational 3D tumor model using eGFP+ target cells. This allows us to couple 3D tumor cell killing by CAR-T-cells to live-cell imaging, providing an efficient quantification of target cell death. As proof- of-concept, we used a 3D model of eGFP+ glioblastoma cells and CAR-T-cells targeting a pan-cancer antigen. This 3D glioblastoma model allowed us to show that classical scFv-based CAR-T-cell therapy of glioblastoma cells can be improved by nanoCAR-T-cells. Furthermore, combining nanoCAR-T-cell therapy with a genetic approach of nanobody-based anti-PD-L1 immune checkpoint blockade further increased the cytotoxicity of the nanoCAR-T-cell therapy.

Related

EURL ECVAM
Projects and initiatives
HealthInnovationPolicy

EURL ECVAM

The EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) promotes and facilitates the use of non-animal methods in testing and research. It validates, disseminates and shares knowledge on the 3Rs (Replacement, Reduction and Refinement of animal experiments). In this video, Raffaella Corvi explains what EURL ECVAM does in the field of safety testing of chemicals while reducing laboratory animal testing. Watch the accessible version of the video here (https://audiovisual.ec.europa.eu/en/video/I-230374). ©European Union, 2021
02:335 months ago
Five simple tricks for making your own video for TPI.tv
TPI.tv videos

Five simple tricks for making your own video for TPI.tv

This video shows you how to make a video yourself. It's really not that difficult! See also the submission page (https://tpi.tv/submit-a-video) for additional information.
01:234 years ago
 Helpathon #11 – Can you help Terry?
Questions
HelpathonsHealth

Helpathon #11 – Can you help Terry?

Terry Vrijenhoek (UMC Utrecht) is a geneticist and explores the societal impact of gene therapy. In this Helpathon the focus is on Alzheimers, for which there is no cure but there is a promising RNA-based therapy in the pipeline. Can you help Terry with designing scenarios for responsible development for gene therapy for Alzheimer disease in terms of benefits, risks, budgets and animal models? More information can be found here (https://www.helpathonhotel.org/coming-up).
01:142 months ago
Helpathon #11 – Can you help Francesca?
Questions
HelpathonsHealth

Helpathon #11 – Can you help Francesca?

Francesca Stillitano (UMC Utrecht) is a geneticist and an Assistant Professor at the Department of Cardiology. Francesca is currently working with mice models and with human tissue-based in vitro models to develop and test new gene therapies for a rare cardiomyopathy. Can you help Francesca with developing gene therapies for curing inherited cardiomyopathies without the use of animal models? More information can be found here (https://www.helpathonhotel.org/coming-up).
01:552 months ago